Current Role of the Total Artificial Heart in the Management of Advanced Heart Failure

2019 ◽  
Vol 21 (11) ◽  
Author(s):  
Nathaniel Melton ◽  
Behzad Soleimani ◽  
Robert Dowling
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Advanced Heart Failure ◽  
Total Artificial Heart ◽  
Current Role

scholarly journals THE TOTAL ARTIFICIAL HEART: AN EFFECTIVE BRIDGE TO TRANSPLANTATION IN PATIENTS WITH ADVANCED HEART FAILURE

2014 ◽  
Vol 63 (12) ◽  
pp. A867 ◽  
Author(s):  
Swaminatha V. Gurudevan ◽  
Francisco Arabia ◽  
Fardad Esmailian ◽  
Danny Ramzy ◽  
Lawrence M. Czer ◽  
...  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Advanced Heart Failure ◽  
Total Artificial Heart ◽  
Bridge To Transplantation

scholarly journals ANMCO POSITION PAPER: Role of intra-aortic balloon pump in patients with acute advanced heart failure and cardiogenic shock

2021 ◽  
Vol 23 (Supplement_C) ◽  
pp. C204-C220
Author(s):  
Roberta Rossini ◽  
Serafina Valente ◽  
Furio Colivicchi ◽  
Cesare Baldi ◽  
Pasquale Caldarola ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiogenic Shock ◽  
Acute Heart Failure ◽  
Advanced Heart Failure ◽  
Position Paper ◽  
Present Position ◽  
Intra Aortic Balloon Pump ◽  
All Cause Mortality ◽  
Practical Recommendations

Abstract The treatment of patients with advanced acute heart failure is still challenging. Intra-aortic balloon pump (IABP) has widely been used in the management of patients with cardiogenic shock. However, according to international guidelines, its routinary use in patients with cardiogenic shock is not recommended. This recommendation is derived from the results of the IABP-SHOCK II trial, which demonstrated that IABP does not reduce all-cause mortality in patients with acute myocardial infarction and cardiogenic shock. The present position paper, released by the Italian Association of Hospital Cardiologists, reviews the available data derived from clinical studies. It also provides practical recommendations for the optimal use of IABP in the treatment of cardiogenic shock and advanced acute heart failure.

Current state of total artificial heart therapy and introduction of the most important total artificial heart systems

2019 ◽  
Vol 64 (3) ◽  
pp. 247-250
Author(s):  
Sotirios Spiliopoulos ◽  
Vera Hergesell ◽  
Andrae Wasler ◽  
Otto Dapunt
Keyword(s):  
Heart Failure ◽  
Organ Donation ◽  
Clinical Outcomes ◽  
Artificial Heart ◽  
Cardiac Transplantation ◽  
Total Artificial Heart ◽  
Successful Implementation ◽  
Technical Requirements ◽  
Current State ◽  
End Stage

AbstractDue to the declining instances of organ donation, total artificial heart (TAH) therapy is of increasing importance for the management of end-stage biventricular heart failure. We introduce the currently most important established and novel TAH systems (SynCardia, CARMAT, ReinHeart, BiVACOR), report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.

The Biocompatibility Challenges in the Total Artificial Heart Evolution

2019 ◽  
Vol 21 (1) ◽  
pp. 85-110 ◽  
Author(s):  
Eleonora Dal Sasso ◽  
Andrea Bagno ◽  
Silvia T.G. Scuri ◽  
Gino Gerosa ◽  
Laura Iop
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Comprehensive Analysis ◽  
Therapeutic Options ◽  
Total Artificial Heart ◽  
Final Treatment ◽  
End Stage Heart Failure ◽  
End Stage

There are limited therapeutic options for final treatment of end-stage heart failure. Among them, implantation of a total artificial heart (TAH) is an acceptable strategy when suitable donors are not available. TAH development began in the 1930s, followed by a dramatic evolution of the actuation mechanisms operating the mechanical pumps. Nevertheless, the performance of TAHs has not yet been optimized, mainly because of the low biocompatibility of the blood-contacting surfaces. Low hemocompatibility, calcification, and sensitivity to infections seriously affect the success of TAHs. These unsolved issues have led to the withdrawal of many prototypes during preclinical phases of testing. This review offers a comprehensive analysis of the pathophysiological events that may occur in the materials that compose TAHs developed to date. In addition, this review illustrates bioengineering strategies to prevent these events and describes the most significant steps toward the achievement of a fully biocompatible TAH.

Sign in / Sign up

Export Citation Format

Share Document